The Patent Finder

Biovec B.V.

Also on record
Records under this name other than patents Biovec B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Biovec B.V.

PatentTitleStatus Expires Confidence
US 8,420,075Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases
Formerly held
Lapsed on the fee record
Ended Apr 16, 2021 · High confidence
Lapsed on the fee recordEnded Apr 16, 2021High confidence
US 7,501,114Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases
Formerly held
Lapsed on the fee record
Ended Mar 10, 2021 · High confidence
Lapsed on the fee recordEnded Mar 10, 2021High confidence
US 8,367,056In Vivo and Ex Vivo Gene Transfer into Renal Tissue Using Gutless Adenovirus Vectors
Formerly held
Lapsed on the fee record
Ended Feb 5, 2021 · Medium confidence
Lapsed on the fee recordEnded Feb 5, 2021Medium confidence
US 7,481,998Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases
Formerly held
Lapsed on the fee record
Ended Jan 27, 2021 · High confidence
Lapsed on the fee recordEnded Jan 27, 2021High confidence
US 8,242,095In Vivo and Ex Vivo Gene Transfer into Renal Tissue Using Gutless Adenovirus Vectors
Formerly held
Lapsed on the fee record
Ended Aug 14, 2020 · Medium confidence
Lapsed on the fee recordEnded Aug 14, 2020Medium confidence
US 8,236,300In Vivo and Ex Vivo Gene Transfer into Renal Tissue Using Gutless Adenovirus Vectors
Formerly held
Lapsed on the fee record
Ended Aug 7, 2020 · Low confidence
Lapsed on the fee recordEnded Aug 7, 2020Low confidence
US 8,048,410In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
Formerly held
Lapsed on the fee record
Ended Nov 1, 2019 · From the USPTO record
Lapsed on the fee recordEnded Nov 1, 2019From the USPTO record
US 7,179,459Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases
Formerly held
Lapsed on the fee record
Ended Feb 20, 2019 · High confidence
Lapsed on the fee recordEnded Feb 20, 2019High confidence
US 7,803,365Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases
Formerly held
Lapsed on the fee record
Ended Sep 28, 2018 · High confidence
Lapsed on the fee recordEnded Sep 28, 2018High confidence
US 7,713,522Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
Formerly held
Lapsed on the fee record
Ended May 11, 2018 · From the USPTO record
Lapsed on the fee recordEnded May 11, 2018From the USPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited